Michael Levine, MD
Nephrology · Los Angeles, CANPI 1740252048
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,531 of the $21,676 with a category attached, or 85.5%. 59 manufacturers reported payments, led by Amgen at 28.4% of the total. Among nephrology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 906 payments — averaging $23.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- AstraZeneca$2K
- Daiichi Sankyo Inc.$1K
- Calliditas Therapeutics US Inc.$820
- Bayer$766
- Boehringer Ingelheim$736
- plus $10K from 53 others
Across 163 payments — averaging $5190.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$210K
- Alnylam Pharmaceuticals Inc.$194K
- CSL Behring$185K
- AstraZeneca$132K
- GSK$81K
- Akebia Therapeutics Inc$31K
- plus $13K from 1 others
What the payments were for
- Speaking & faculty fees$3,06514%
- Travel & lodging$300%
- Food & beverage$18,53185%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,676 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 252 | $286,128 |
| MounjaroTirzepatide | 107 | $138,103 |
| JardianceEmpagliflozin | 74 | $97,620 |
| Repatha SureclickEvolocumab | 98 | $90,195 |
| KerendiaFinerenone | 71 | $86,449 |
| OzempicSemaglutide | 69 | $84,282 |
| EliquisApixaban | 55 | $71,725 |
| XphozahTenapanor Hcl | 15 | $42,096 |
| JanuviaSitagliptin Phosphate | 33 | $38,810 |
| Sevelamer Carbonate | 51 | $28,545 |
| XareltoRivaroxaban | 18 | $23,670 |
| EntrestoSacubitril/Valsartan | 19 | $22,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $21,681 |
| TradjentaLinagliptin | 21 | $21,238 |
| TrulicityDulaglutide | 11 | $17,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Crestor | $2,048 | $298,023266 claims |
| Lilly USA, LLCMounjaro, Trulicity | $494 | $155,722118 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy | $736 | $138,462124 claims |
| BayerKerendia | $766 | $86,44971 claims |
| Novo NordiskOzempic | $179 | $84,28269 claims |
| PfizerEliquis | $200 | $71,72555 claims |
| MerckJanuvia, Belsomra | $288 | $47,06154 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $590 | $27,40136 claims |
| Johnson & JohnsonXarelto | $258 | $23,67018 claims |
| NovartisEntresto | $639 | $22,33719 claims |
| AbbVieLinzess, Synthroid | $362 | $17,46172 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $63 | $15,78729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$2.2M
- Suphamai BunnapradistLos Angeles$498K
- Mohammad KamgarLos Angeles$497K
- Victor CarabelloLos Angeles$363K
- Tariq ShahLos Angeles$351K
- Susanne NicholasLos Angeles$146K
- Arishia GhaffariLos Angeles$142K
- Allen NissensonLos Angeles$101K
- Niloofar NobakhtLos Angeles$97K
- Farid ArmanLos Angeles$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.